Momtchilo Russo, Maria Cássia Mendes-Corrêa, Bruna B Lins, Victor Kersten, Paulo C A Pernambuco Filho, Toni Ricardo Martins, Tânia Regina Tozetto-Mendoza, Lucy Santos Vilas Boas, Brisa Moreira Gomes, Livia Mendonça Munhoz Dati, Amaro Nunes Duarte-Neto, Gustavo Roncoli Reigado, Ana Beatriz T Frederico, Danielle R de A de Brito E Cunha, Anderson Vicente de Paula, José Igor G da Silva, Carlos F Moreira Vasconcelos, Felipe S Chambergo, Viviane Abreu Nunes, Ana Paula Dinis Ano Bom, Leda R Castilho, Rodrigo A P Martins, Mario Hiroyuki Hirata, Luciana Mirotti
Mucosal vaccination appears to be suitable to protect against SARS-CoV-2 infection. In this study, we tested an intranasal mucosal vaccine candidate for COVID-19 that consisted of a cationic liposome containing a trimeric SARS-CoV-2 spike protein and CpG-ODNs, a Toll-like receptor 9 agonist, as an adjuvant. In vitro and in vivo experiments indicated the absence of toxicity following the intranasal administration of this vaccine formulation. First, we found that subcutaneous or intranasal vaccination protected hACE-2 transgenic mice from infection with the wild-type (Wuhan) SARS-CoV-2 strain, as shown by weight loss and mortality indicators...
November 20, 2023: Vaccines